The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

Quattro Financial Advisors LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.7% during the ...

Avitas Wealth Management LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 39.2% in the ...